ANI Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
ANI Pharmaceuticals's earnings have been declining at an average annual rate of -31.3%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 17.7% per year. ANI Pharmaceuticals's return on equity is 4.1%, and it has net margins of 3.2%.
Key information
-31.3%
Earnings growth rate
-30.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 17.7% |
Return on equity | 4.1% |
Net Margin | 3.2% |
Next Earnings Update | 10 May 2024 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28ANI Pharma launches generic Prochlorperazine maleate tablets
Aug 29ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval
Aug 16ANI Pharmaceuticals Q2 2022 Earnings Preview
Aug 05ANI Pharmaceuticals (NASDAQ:ANIP) Is Making Moderate Use Of Debt
Apr 29ANI Pharmaceuticals: Back In The Buy Zone
Feb 08Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Nov 02Revenue & Expenses BreakdownBeta
How ANI Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 487 | 15 | 162 | 34 |
30 Sep 23 | 449 | 10 | 150 | 30 |
30 Jun 23 | 401 | -8 | 138 | 26 |
31 Mar 23 | 359 | -28 | 132 | 23 |
31 Dec 22 | 316 | -50 | 115 | 22 |
30 Sep 22 | 283 | -69 | 112 | 20 |
30 Jun 22 | 251 | -65 | 99 | 15 |
31 Mar 22 | 226 | -63 | 86 | 14 |
31 Dec 21 | 216 | -43 | 84 | 11 |
30 Sep 21 | 212 | -22 | 61 | 12 |
30 Jun 21 | 213 | -17 | 66 | 16 |
31 Mar 21 | 213 | -15 | 62 | 13 |
31 Dec 20 | 208 | -23 | 65 | 16 |
30 Sep 20 | 199 | -24 | 65 | 17 |
30 Jun 20 | 198 | -20 | 57 | 15 |
31 Mar 20 | 203 | -1 | 56 | 19 |
31 Dec 19 | 207 | 6 | 56 | 20 |
30 Sep 19 | 216 | 16 | 55 | 18 |
30 Jun 19 | 215 | 17 | 53 | 17 |
31 Mar 19 | 208 | 14 | 48 | 18 |
31 Dec 18 | 202 | 15 | 44 | 15 |
30 Sep 18 | 192 | 0 | 40 | 13 |
30 Jun 18 | 189 | 0 | 36 | 11 |
31 Mar 18 | 187 | 0 | 33 | 10 |
31 Dec 17 | 177 | -1 | 32 | 9 |
30 Sep 17 | 168 | 7 | 30 | 7 |
30 Jun 17 | 158 | 5 | 29 | 5 |
31 Mar 17 | 145 | 4 | 28 | 4 |
31 Dec 16 | 129 | 4 | 27 | 3 |
30 Sep 16 | 108 | 8 | 25 | 3 |
30 Jun 16 | 90 | 10 | 23 | 3 |
31 Mar 16 | 78 | 12 | 22 | 3 |
31 Dec 15 | 76 | 15 | 21 | 3 |
30 Sep 15 | 79 | 33 | 20 | 3 |
30 Jun 15 | 77 | 35 | 19 | 3 |
31 Mar 15 | 64 | 30 | 18 | 3 |
31 Dec 14 | 56 | 29 | 17 | 3 |
30 Sep 14 | 45 | 11 | 15 | 3 |
30 Jun 14 | 36 | 5 | 14 | 2 |
31 Mar 14 | 35 | 1 | 12 | 2 |
31 Dec 13 | 30 | -5 | 11 | 2 |
30 Sep 13 | 25 | -12 | 9 | 2 |
30 Jun 13 | 22 | -16 | 9 | 1 |
Quality Earnings: ANIP has high quality earnings.
Growing Profit Margin: ANIP became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANIP has become profitable over the past 5 years, growing earnings by -31.3% per year.
Accelerating Growth: ANIP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ANIP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: ANIP's Return on Equity (4.1%) is considered low.